Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 20.53
(3.53%)
CNY 20.53
(3.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.22 Billion CNY | -6095.95% |
| 2022 | 20.45 Million CNY | -92.19% |
| 2021 | 261.99 Million CNY | -15.26% |
| 2020 | 309.19 Million CNY | 17.83% |
| 2019 | 262.4 Million CNY | 51.95% |
| 2018 | 172.68 Million CNY | -26.69% |
| 2017 | 235.56 Million CNY | 18.45% |
| 2016 | 198.86 Million CNY | 14.11% |
| 2015 | 174.26 Million CNY | 18.16% |
| 2014 | 147.48 Million CNY | 11.52% |
| 2013 | 132.25 Million CNY | 24.65% |
| 2012 | 106.09 Million CNY | 38.2% |
| 2011 | 76.76 Million CNY | 13.83% |
| 2010 | 67.44 Million CNY | 56.19% |
| 2009 | 43.17 Million CNY | 289.81% |
| 2008 | 11.07 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 12.38 Million CNY | 120.8% |
| 2024 Q3 | -13.27 Million CNY | -207.22% |
| 2024 Q1 | -59.52 Million CNY | 92.74% |
| 2023 Q1 | 5.75 Million CNY | 108.75% |
| 2023 Q2 | -168.86 Million CNY | -3035.41% |
| 2023 FY | -1.22 Billion CNY | -6095.95% |
| 2023 Q3 | -243.16 Million CNY | -44.0% |
| 2023 Q4 | -820.04 Million CNY | -237.24% |
| 2022 Q3 | 5.32 Million CNY | -88.82% |
| 2022 FY | 20.45 Million CNY | -92.19% |
| 2022 Q4 | -65.75 Million CNY | -1335.46% |
| 2022 Q2 | 47.6 Million CNY | 43.02% |
| 2022 Q1 | 33.28 Million CNY | 13.08% |
| 2021 Q1 | 83.21 Million CNY | 17.64% |
| 2021 FY | 261.99 Million CNY | -15.26% |
| 2021 Q3 | 54.95 Million CNY | -41.78% |
| 2021 Q2 | 94.39 Million CNY | 13.43% |
| 2021 Q4 | 29.43 Million CNY | -46.44% |
| 2020 FY | 309.19 Million CNY | 17.83% |
| 2020 Q1 | 63.82 Million CNY | 45.03% |
| 2020 Q4 | 70.73 Million CNY | -18.52% |
| 2020 Q3 | 86.81 Million CNY | -1.14% |
| 2020 Q2 | 87.81 Million CNY | 37.6% |
| 2019 Q2 | 72.9 Million CNY | 11.74% |
| 2019 FY | 262.4 Million CNY | 51.95% |
| 2019 Q1 | 65.24 Million CNY | 578.54% |
| 2019 Q3 | 80.24 Million CNY | 10.06% |
| 2019 Q4 | 44 Million CNY | -45.16% |
| 2018 Q1 | 57 Million CNY | -26.96% |
| 2018 Q2 | 67.28 Million CNY | 18.02% |
| 2018 Q4 | -13.63 Million CNY | -121.98% |
| 2018 Q3 | 62.02 Million CNY | -7.82% |
| 2018 FY | 172.68 Million CNY | -26.69% |
| 2017 Q3 | 57.65 Million CNY | 18.21% |
| 2017 FY | 235.56 Million CNY | 18.45% |
| 2017 Q1 | 51.08 Million CNY | -35.9% |
| 2017 Q4 | 78.04 Million CNY | 35.37% |
| 2017 Q2 | 48.77 Million CNY | -4.52% |
| 2016 Q4 | 79.69 Million CNY | 104.56% |
| 2016 FY | 198.86 Million CNY | 14.11% |
| 2016 Q1 | 34.48 Million CNY | -56.92% |
| 2016 Q3 | 38.96 Million CNY | -14.79% |
| 2016 Q2 | 45.72 Million CNY | 32.6% |
| 2015 Q1 | 26.61 Million CNY | -61.11% |
| 2015 Q4 | 80.03 Million CNY | 170.18% |
| 2015 Q3 | 29.62 Million CNY | -22.03% |
| 2015 Q2 | 37.99 Million CNY | 42.75% |
| 2015 FY | 174.26 Million CNY | 18.16% |
| 2014 Q4 | 68.43 Million CNY | 256.39% |
| 2014 FY | 147.48 Million CNY | 11.52% |
| 2014 Q1 | 24.22 Million CNY | -54.2% |
| 2014 Q2 | 35.62 Million CNY | 47.08% |
| 2014 Q3 | 19.2 Million CNY | -46.11% |
| 2013 Q4 | 52.89 Million CNY | 208.03% |
| 2013 FY | 132.25 Million CNY | 24.65% |
| 2013 Q1 | 24.2 Million CNY | -41.55% |
| 2013 Q2 | 37.98 Million CNY | 56.97% |
| 2013 Q3 | 17.17 Million CNY | -54.8% |
| 2012 Q3 | 14.28 Million CNY | -52.31% |
| 2012 Q2 | 29.94 Million CNY | 46.31% |
| 2012 Q1 | 20.46 Million CNY | -8.38% |
| 2012 FY | 106.09 Million CNY | 38.2% |
| 2012 Q4 | 41.4 Million CNY | 189.92% |
| 2011 Q3 | 6.31 Million CNY | -79.18% |
| 2011 Q4 | 22.34 Million CNY | 253.51% |
| 2011 FY | 76.76 Million CNY | 13.83% |
| 2011 Q2 | 30.35 Million CNY | 70.9% |
| 2011 Q1 | 17.75 Million CNY | -16.67% |
| 2010 Q3 | 14.58 Million CNY | 0.0% |
| 2010 FY | 67.44 Million CNY | 56.19% |
| 2010 Q4 | 21.31 Million CNY | 46.11% |
| 2009 FY | 43.17 Million CNY | 289.81% |
| 2008 FY | 11.07 Million CNY | 0.0% |